Advicenne (ALDVI) - Total Assets
Based on the latest financial reports, Advicenne (ALDVI) holds total assets worth €6.73 Million EUR (≈ $7.87 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Advicenne - Total Assets Trend (2014–2024)
This chart illustrates how Advicenne's total assets have evolved over time, based on quarterly financial data. Also see ALDVI stock market capitalisation for the company's overall valuation and market capitalisation.
Advicenne - Asset Composition Analysis
Current Asset Composition (December 2024)
Advicenne's total assets of €6.73 Million consist of 92.6% current assets and 7.4% non-current assets. Review ALDVI current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €3.25 Million | 34.2% |
| Accounts Receivable | €3.73 Million | 39.3% |
| Inventory | €1.68 Million | 17.7% |
| Property, Plant & Equipment | €225.93K | 2.4% |
| Intangible Assets | €302.00K | 3.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Advicenne's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Advicenne stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Advicenne's current assets represent 92.6% of total assets in 2024, an increase from 91.0% in 2014.
- Cash Position: Cash and equivalents constituted 34.2% of total assets in 2024, down from 46.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 39.3% of total assets.
Advicenne Competitors by Total Assets
Key competitors of Advicenne based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.78 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
Advicenne - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.59 | 0.36 | 3.42 |
| Quick Ratio | 0.45 | 0.26 | 3.34 |
| Cash Ratio | 0.05 | 0.11 | 2.74 |
| Working Capital | €-4.24 Million | €-11.69 Million | €15.79 Million |
Advicenne - Advanced Valuation Insights
This section examines the relationship between Advicenne's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 127.70 |
| Latest Market Cap to Assets Ratio | 1.55 |
| Asset Growth Rate (YoY) | -23.4% |
| Total Assets | €9.51 Million |
| Market Capitalization | $14.73 Million USD |
Valuation Analysis
Above Book Valuation: The market values Advicenne's assets above their book value (1.55x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Advicenne's assets decreased by 23.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Advicenne (2014–2024)
The table below shows the annual total assets of Advicenne from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €9.51 Million ≈ $11.11 Million |
-23.37% |
| 2023-12-31 | €12.41 Million ≈ $14.51 Million |
-12.99% |
| 2022-12-31 | €14.26 Million ≈ $16.67 Million |
-24.48% |
| 2021-12-31 | €18.88 Million ≈ $22.07 Million |
-21.34% |
| 2020-12-31 | €24.00 Million ≈ $28.06 Million |
+4.73% |
| 2019-12-31 | €22.92 Million ≈ $26.80 Million |
-30.91% |
| 2018-12-31 | €33.17 Million ≈ $38.78 Million |
-14.09% |
| 2017-12-31 | €38.62 Million ≈ $45.15 Million |
+1086.02% |
| 2016-12-31 | €3.26 Million ≈ $3.81 Million |
+9.26% |
| 2015-12-31 | €2.98 Million ≈ $3.48 Million |
-7.51% |
| 2014-12-31 | €3.22 Million ≈ $3.77 Million |
-- |
About Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or co… Read more